Not available
Quote | Editas Medicine Inc. (NASDAQ:EDIT)
Last: | $5.62 |
---|---|
Change Percent: | 0.0% |
Open: | $5.89 |
Close: | $5.62 |
High: | $5.935 |
Low: | $5.585 |
Volume: | 1,739,832 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
News | Editas Medicine Inc. (NASDAQ:EDIT)
2024-05-15 20:25:24 ET Editas Medicine, Inc. (EDIT) RBC Capital Markets Global Healthcare Conference Call May 15, 2024 14:05 ET Company Participants Gilmore O’Neill - Chief Executive Officer Conference Call Participants Luca Issi - RBC Capital Markets ...
2024-05-15 08:58:29 ET Summary Editas Medicine shares have underperformed the S&P 500 by over 108% in the last three years. The company has a promising pipeline and is making strides in preclinical and clinical trials. However, weak financials and the risk associated with ...
Message Board Posts | Editas Medicine Inc. (NASDAQ:EDIT)
Subject | By | Source | When |
---|---|---|---|
Could be upcoming https://annualmeeting.asgct.org/program/agenda-details?agendaI | jondoeuk | investorshub | 04/13/2023 10:21:36 PM |
Does this have any FDA approvals? | jondoeuk | investorshub | 03/19/2023 7:39:22 PM |
Does this have any FDA approvals? Will Precision | rtrstock | investorshub | 03/07/2023 6:59:07 PM |
PR https://www.globenewswire.com/news-release/2022/05/18/2445810/0/en/Editas-Med | jondoeuk | investorshub | 05/19/2022 5:39:30 PM |
1106: $EDIT-202, a Multiplexed CRISPR-Cas12a Gene-Edited iPSC-Derived NK | jondoeuk | investorshub | 05/02/2022 9:43:49 PM |
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced ...
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and EdiTHAL trials of renizga...
Research includes the first-ever application of AsCas12a in vivo, optimized LNP delivery, and gene editing RNA guide modifications Data to support...